Related Experiment Video
Updated: Jul 30, 2025
High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
A Method for the In Vitro Cytotoxicity Assessment of Anti-cancer Compounds and Materials Using High Content Screening
Melissa Anne Tutty1,2, Adriele Prina-Mello3,4,5,6
1Laboratory for Biological Characterization of Advanced Materials (LBCAM), Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, Trinity College Dublin, Dublin, Ireland.
Abstract:
To date, there is a large bottleneck associated with cancer drug design and development: a lack of appropriate methodologies for screening their potential toxicity. This issue not only causes a high attrition rate for these compounds but also slows down the drug discovery process in general. To overcome this problem, robust, accurate, and reproducible methodologies for assessing anti-cancer compounds are essential. Multiparametric technique and high-throughput analysis, in particular, are favored due to the time- and cost-effective way in which they assess large panels of materials, and due to their large informational output. Following extensive work within our group, we have developed a protocol for assessing the toxicity of anti-cancer compounds using a high-content screening and analysis (HCSA) platform, which is both time-effective and reproducible.
Insights
Developing new cancer drugs is slowed by toxicity screening challenges. A new high-content screening and analysis (HCSA) protocol offers a reproducible and efficient method for assessing anti-cancer compound toxicity.
Area of Science:
- Drug Discovery and Development
- Toxicology
- Computational Biology
Background:
- A significant bottleneck in cancer drug design is the lack of effective toxicity screening methods.
- This deficiency leads to high compound attrition rates and delays the overall drug discovery pipeline.
- Robust, accurate, and reproducible toxicity assessment methodologies are crucial for advancing anti-cancer drug development.
Purpose of the Study:
- To address the limitations in current anti-cancer compound toxicity screening.
- To develop and present a novel, efficient, and reproducible protocol for toxicity assessment.
- To leverage high-content screening and analysis for improved drug safety evaluation.
Main Methods:
- Development of a protocol utilizing a high-content screening and analysis (HCSA) platform.
- Application of multiparametric techniques and high-throughput analysis for comprehensive material assessment.
- Focus on time- and cost-effectiveness in evaluating large compound panels.
Main Results:
- A novel protocol for assessing anti-cancer compound toxicity has been successfully developed.
- The HCSA platform provides a time-effective and reproducible method for toxicity screening.
- The developed protocol is suitable for evaluating large numbers of potential anti-cancer agents.
Conclusions:
- The developed HCSA protocol effectively addresses the need for improved toxicity screening in anti-cancer drug development.
- This methodology offers a significant advancement in efficiently and reliably assessing compound safety.
- The protocol has the potential to reduce attrition rates and accelerate the drug discovery process.
More Related Videos
12:22A Strategy to Identify Compounds that Affect Cell Growth and Survival in Cultured Mammalian Cells at Low-to-Moderate Throughput
Published on: September 22, 2019
11:38High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
Published on: May 10, 2016